Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FASN | P49327 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475136 | 1.00 | MAPT (0.52) | MAPTALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL5481270 | 0.87 | HTT (0.50) | MAPTALDH1A1POLBKDM4EHTT | |
| SCHEMBL5481267 | 0.87 | HTT (0.50) | MAPTALDH1A1POLBKDM4EHTT | |
| SCHEMBL5470754 | 0.83 | MAPT (0.59) | MAPTALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL5477436 | 0.83 | MAPT (0.59) | MAPTALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL5475174 | 0.83 | MAPT (0.59) | MAPTALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL5478093 | 0.83 | MAPT (0.59) | MAPTALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL5470757 | 0.83 | MAPT (0.59) | MAPTALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL5474311 | 0.79 | HSD11B1 (0.68) | ALDH1A1KMT2APOLBKDM4EHSD11B1 | |
| SCHEMBL5474315 | 0.79 | HSD11B1 (0.68) | ALDH1A1KMT2APOLBKDM4EHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | MAPT 4016/4885ALDH1A1 68/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.